Nonsteroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas
Authors:
- 19 April 2004
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2021 (10) , CD004079
Abstract
There is evidence from experimental animals studies, prospective and retrospective observational studies that nonsteroidal anti-inflammatory drugs (NSAIDS) may reduce the development of sporadic colorectal adenomas (CRAs) and cancer (CRC) and may induce the regression of adenomas in familial adenomatous polyposis (FAP). To conduct a systematic review to determine the effect of NSAIDS for the prevention or regression of CRAs and CRC. Randomized controlled trials (RCTs) up to September 2003 were identified. NSAIDS and aspirin (ASA) were the interventions. The primary outcomes were the number of subjects with at least one CRA, the change in polyp burden, and CRC. The secondary outcome was adverse events. Two reviewers independently extracted data and assessed trial quality. Dichotomous outcomes were reported as relative risks (RR) with 95% confidence intervals (CI). The data were combined with the random effects model if clinically and statistically reasonable. Nine trials with 150 familial adenomatous polyposis (FAP) and 24,143 population subjects met the inclusion criteria. The interventions included sulindac, celecoxib, or aspirin (ASA). From the combined results of three trials, significantly fewer subjects in the low dose ASA group developed recurrent sporadic CRAs [RR 0.77 (95% CI 0.61, 0.96), (NNT 12.5 (95% CI 7.7, 25)] after one to three years. In another three trials, phenotypic FAP subjects that received sulindac or celecoxib had a greater proportional reduction (range: 11.9% to 44%) in the number of CRAs compared to those in the control group (range: 4.5% to 10%). There was no significant difference for the outcomes of CRC or adverse events in any of the trials. There was evidence from three pooled RCTs that ASA significantly reduces the recurrence of sporadic adenomatous polyps after one to three years. There is evidence from short-term studies to support regression, but not elimination or prevention of CRAs in FAP.Keywords
This publication has 40 references indexed in Scilit:
- Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial1 1The authors thank the women and men who participated in the study, P. E. Douziech for coordination of treatments, and the hospital pharmacists for preparation of the treatments in the trial centers.Gastroenterology, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal AdenomasNew England Journal of Medicine, 2003
- Do NSAIDs Prevent Colorectal Cancer?Canadian Journal of Gastroenterology and Hepatology, 2000
- Design of the Women’s Health Initiative Clinical Trial and Observational StudyControlled Clinical Trials, 1998
- Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapyGastroenterology, 1994
- Low-Dose Aspirin and Incidence of Colorectal Tumors in a Randomized TrialJNCI: Journal of the National Cancer Institute, 1993
- Treatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous PolyposisNew England Journal of Medicine, 1993
- Sulindac causes regression of rectal polyps in familial adenomatous polyposisGastroenterology, 1991
- Preliminary Report: Findings from the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1988
- Natural history of untreated colonic polypsGastroenterology, 1987